Can Nesfatin-1 Predict Hypertension in Obese Children?
The prevalence of childhood obesity is increasing and, it brings co-morbidities like hypertension. However, it is still not clear whether some obese individuals are hypertensive and others do not. Nesfatin-1 is a recently discovered anorexigenic peptide which also has effects on blood pressure. Our aim is to evaluate the relationship between obesity-related hypertension and Nesfatin-1. For this cross-sectional study 87 obese children were included. The patients were divided into two groups as hypertensive (n=30) and normotensive (n=57) obese. We used the American Academy of Pediatrics guidelines to diagnose hypertension. Blood samples were collected after 12 hours of fasting to examine the levels of Nesfatin-1. We also evaluated the serum trace elements of the patients besides the routine blood tests. Body mass index (BMI), weight and serum Nesfatin-1 were higher in the hypertensive group (p=0.002, p=0.001, and p=0.007 respectively). There was no difference between serum zinc levels but copper levels were significantly lower in the hypertensive group (p=0.248, p=0.007, respectively). There was a positive correlation between blood pressure and BMI and weight z scores and a negative correlation with Cu. The optimal cut-off value of Nesfatin-1 to predict hypertension was found to be >1.8 ng/ml, with specificity of 71.9% and sensitivity of 96.7% (AUC=0.703; 95% CI, 0.577-0.809; p=0.002). In the multiple logistic regression analysis Nesfatin-1 (OR=1.103, 95% CI: 1.039-1.171, p=0.001), Cu (OR=0.947, 95% CI: 0.915-0.979, p=0.001) and BMI for age z score (OR=56.277, 95% CI: 5.791-546.907, p=0.001) still remained significant predictors of hypertension. We found Nesfatin-1 was higher and Nesfatin-1 levels independently predict hypertension in obese subjects.